Argatroban therapy for heparin-induced thrombocytopenia during pregnancy in a woman with hereditary antithrombin deficiency

Journal of Obstetrics and Gynaecology Research

Volumn 38, Issue 4, 2012, Pages 749-752

  Tanimura, Kenji ^a   Ebina, Yashuhiko ^a   Sonoyama, Ayako ^a   Morita, Hiroki ^a   Miyata, Shigeki ^b   Yamada, Hideto ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Antithrombin deficiency; Argatroban; Fondaparinux; Heparin induced thrombocytopenia

Indexed keywords

ANTITHROMBIN; ARGATROBAN; FONDAPARINUX; HEPARIN; OXYTOCIN; UROKINASE; WARFARIN;

ADULT; ANTITHROMBIN DEFICIENCY; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DNA DETERMINATION; DOPPLER FLOWMETRY; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION DISORDERS, INHERITED; FEMALE; HEPARIN; HUMANS; MALE; PIPECOLIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 84860859062     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2011.01758.x     Document Type: Article

References (21)

1. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14: 127-141. (Pubitemid 12127989)
2. Brenner B, Tavori S, Tatarsky I. Prophylaxis of thromboembolism during pregnancy in hereditary AT III deficiency. Am J Hematol 1992; 39: 71-72.
3. Yamada T, Yamada H, Morikawa M et al. Management of pregnancy with congenital antithrombin III deficiency: Two case reports and a review of the literature. J Obstet Gynaecol Res 2001; 27: 189-197. (Pubitemid 33034793)
4. Greinacher A. Heparin-induced thrombocytopenia: Frequency and pathogenesis. Pathophysiol Haemost Thromb 2006; 35: 37-45.
5. Fausett MB, Vogtlander M, Lee RM et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001; 185: 148-152. (Pubitemid 32681809)
6. Chowdhury V, Olds RJ, Lane DA et al. Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haematol 1993; 84: 656-661. (Pubitemid 23248058)
7. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis and management. Br J Haematol 2003; 121: 535-555. (Pubitemid 36645375)
8. Mehta R, Golichowski A. Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy. J Thromb Haemost 2004; 2: 1665-1666. (Pubitemid 40186186)
9. Gill J, Kovacs MJ. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet Gynecol 1997; 90: 648-650. (Pubitemid 27413288)
10. Gerhardt A, Scharf RE, Zotz RB. Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia type II (HIT). Clin Appl Thromb Hemost 2009; 15: 461-464.
11. Schindewolf M, Lindhoff-Last E. Alternative anticoagulation with danaparoid in two pregnancies in a patient with former heparin-induced thrombocytopenia (HIT), homozygous factor V Leiden mutation, a history of venous thrombosis and recurrent pregnancy losses. Thromb Haemost 2008; 99: 776-778. (Pubitemid 351694235)
12. Pouplard C, Gueret P, Fouassier M et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 5: 1373-1379. (Pubitemid 46965362)
13. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? J Lab Clin Med 2005; 146: 341-346. (Pubitemid 41712020)
14. Greinacher A, Juhl D, Strobel U et al. Heparin-induced thrombocytopenia: A prospective study on the incidence, plateletactivating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5: 1666-1673. (Pubitemid 47091409)
15. Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJ. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 1260-1265.
16. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis 2000; 10 (Suppl 1): 35-45.
17. Mazzolai L, Hohlfeld P, Mazzolai L et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108: 1569-1570. (Pubitemid 44316123)
18. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843. (Pubitemid 32328395)
19. Young SK, Al-Mandhiry HA, Vaida ST, Ambrose A, Bottie JJ. Successful use of argatroban during the third-trimester of pregnancy: Case report and review of the literature. Pharmacotherapy 2009; 28: 1532-1536.
20. Ekbatani A, Asaro LR, Malinow AM. Anticoagulation with argatroban in a parturient with heparin-induced thrombocytopenia. Int J Obstet Anesth 2010; 19: 82-87.
21. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350: 1914-1915.